Associations of serum uric acid levels and anthropometric parameters with non-alcoholic fatty liver disease in healthy individuals: innovative insights from a cross-sectional study

References

• Pouwels S, Sakran N, Graham Y, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and weight loss effects. BMC Endocr Disord. 2022;22(1):63. doi:10.1186/s12902-022-00980-1.
   PubMed Web of Science ®Google Scholar
• Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021; Jun397(10290):2212–2224. doi:10.1016/S0140-6736(20)32511-3.
   PubMed Web of Science ®Google Scholar
• Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(6):2672–2682. doi:10.1002/hep.30251.
   PubMed Web of Science ®Google Scholar
• Değertekin B, Tozun N, Demir F, et al. The changing prevalence of non-alcoholic fatty liver disease (NAFLD) in Turkey in the last decade. Turk J Gastroenterol. 2021;32(3):302–312. doi:10.5152/tjg.2021.20062.
   PubMed Web of Science ®Google Scholar
• Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44(4):865–873. doi:10.1002/hep.21327.
   PubMed Web of Science ®Google Scholar
• Targher G, Tilg H, Byrne CD. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol. 2021;6(7):578–588. doi:10.1016/S2468-1253(21)00020-0.
   PubMed Web of Science ®Google Scholar
• Tarantino G, Crocetto F, Di Vito C, et al. Association of NAFLD and insulin resistance with non-Metastatic bladder cancer patients: a cross-sectional retrospective study. J Clin Med. 2021;10(2):346. doi:10.3390/jcm10020346.
   PubMed Web of Science ®Google Scholar
• Yuan S, Chen J, Li X, et al. Lifestyle and metabolic factors for nonalcoholic fatty liver disease: mendelian randomization study. Eur J Epidemiol. 2022;37(7):723–733. doi:10.1007/s10654-022-00868-3.
   PubMed Web of Science ®Google Scholar
• Lima WG, Martins-Santos ME, Chaves VE. Uric acid as a modulator of glucose and lipid metabolism. Biochimie. 2015;116:17–23. doi:10.1016/j.biochi.2015.06.025.
   PubMed Web of Science ®Google Scholar
• Feig DI, Kang D, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359(17):1811–1821. doi:10.1056/NEJMra0800885.
   PubMed Web of Science ®Google Scholar
• Gaffo AL, Edwards NL, Saag KG. Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link? Arthritis Res Ther. 2009;11(4):240. doi:10.1186/ar2761.
   PubMed Web of Science ®Google Scholar
• Edwards NL. The role of hyperuricemia in vascular disorders. Curr Opin Rheumatol. 2009;21(2):132–137. doi:10.1097/BOR.0b013e3283257b96.
   PubMed Web of Science ®Google Scholar
• Sun Q, Zhang T, Manji L, et al. Association between serum uric acid and non-alcoholic fatty liver disease: an updated systematic review and meta-analysis. Clin Epidemiol. 2023;15:683–693. doi:10.2147/CLEP.S403314.
   PubMed Web of Science ®Google Scholar
• Huang F, Liu A, Fang H, et al. Serum uric acid levels in non-alcoholic steatosis patients: a meta-analysis. Asia Pac J Clin Nutr. 2017;26(2):334–342.
   PubMed Web of Science ®Google Scholar
• Feng Y, Zheng S, Liu L, et al. Association of serum uric acid with hepatic steatosis detected by controlled attenuation parameter in the United States population. Lipids Health Dis. 2023;22(1):76. doi:10.1186/s12944-023-01846-8.
   PubMed Web of Science ®Google Scholar
• Xie D, Zhao H, Lu J, et al. High uric acid induces liver fat accumulation via ROS/JNK/AP-1 signaling. Am J Physiol Endocrinol Metab. 2021;320(6):E1032–E1043. doi:10.1152/ajpendo.00518.2020.
   PubMed Web of Science ®Google Scholar
• Almeida NS, Rocha R, Cotrim HP, et al. Anthropometric indicators of visceral adiposity as predictors of non-alcoholic fatty liver disease: a review. World J Hepatol. 2018;10(10):695–701. doi:10.4254/wjh.v10.i10.695.
   PubMed Web of Science ®Google Scholar
• Xu R, Pan J, Zhou W, et al. Recent advances in lean NAFLD. Biomed Pharmacother. 2022;153:113331. doi:10.1016/j.biopha.2022.113331.
   PubMed Web of Science ®Google Scholar
• Lee DH. Imaging evaluation of non-alcoholic fatty liver disease: focused on quantification. Clin Mol Hepatol. 2017;23(4):290–301. doi:10.3350/cmh.2017.0042.
   PubMed Web of Science ®Google Scholar
• Jebb SA, Cole TJ, Doman D, et al. Evaluation of the novel tanita body-fat analyser to measure body composition by comparison with a four-compartment model. Br J Nutr. 2000;83(2):115–122. doi:10.1017/s0007114500000155.
   PubMed Web of Science ®Google Scholar
• Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54(3):1082–1090. doi:10.1002/hep.24452.
   PubMed Web of Science ®Google Scholar
• Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547–1554. doi:10.1002/hep.27368.
   PubMed Web of Science ®Google Scholar
• Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797–1835. doi:10.1097/HEP.0000000000000323.
   PubMed Web of Science ®Google Scholar
• Schiffrin M, Winkler C, Quignodon L, et al. Sex dimorphism of nonalcoholic fatty liver disease (NAFLD) in Pparg-null mice. Int J Mol Sci. 2021;22(18):9969. doi:10.3390/ijms22189969.
   PubMed Web of Science ®Google Scholar
• Della Torre S. Beyond the X factor: relevance of sex hormones in NAFLD pathophysiology. Cells. 2021;10(9):2502. doi:10.3390/cells10092502.
   PubMed Web of Science ®Google Scholar
• Della Torre S. Non-alcoholic fatty liver disease as a canonical example of metabolic inflammatory-based liver disease showing a sex-specific prevalence: relevance of estrogen signaling. Front Endocrinol (Lausanne). 2020;11:572490. doi:10.3389/fendo.2020.572490.
   PubMed Web of Science ®Google Scholar
• Pimenta NM, Santa-Clara H, Melo X, et al. Waist-to-hip ratio is related to body fat content and distribution regardless of the waist circumference measurement protocol in nonalcoholic fatty liver disease patients. Int J Sport Nutr Exerc Metab. 2016;26(4):307–314. doi:10.1123/ijsnem.2014-0256.
   PubMed Web of Science ®Google Scholar
• Borges-Canha M, Neves JS, Silva MM et al. Waist-to-hip ratio and inflammatory parameters are associated with risk of non-alcoholic fatty liver disease in patients with morbid obesity. Biomedicines. 2022;10(10):2416. doi:10.3390/biomedicines10102416.
   PubMed Web of Science ®Google Scholar
• Cai J, Lin C, Lai S, et al. Waist-to-height ratio, an optimal anthropometric indicator for metabolic dysfunction associated fatty liver disease in the Western Chinese male population. Lipids Health Dis. 2021;20(1):145. doi:10.1186/s12944-021-01568-9.
   PubMed Web of Science ®Google Scholar
• Zheng RD, Chen ZR, Chen JN, et al. Role of body mass index, waist-to-height and waist-to-hip ratio in prediction of nonalcoholic fatty liver disease. Gastroenterol Res Pract. 2012;2012:362147–362146. doi:10.1155/2012/362147.
   PubMed Web of Science ®Google Scholar
• Lonardo A, Loria P, Leonardi F, et al. Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study. Dig Liver Dis. 2002;34(3):204–211. doi:10.1016/s1590-8658(02)80194-3.
   PubMedGoogle Scholar
• Darmawan G, Hamijoyo L, Hasan I. Association between serum uric acid and non-alcoholic fatty liver disease: a meta-analysis. Acta Med Indones. 2017;49(2):136–147.
   PubMed Web of Science ®Google Scholar
• Liu Z, Que S, Zhou L, et al. Dose-response relationship of serum uric acid with metabolic syndrome and non-alcoholic fatty liver disease incidence: a meta-analysis of prospective studies. Sci Rep. 2015;5(1):14325. doi:10.1038/srep14325.
   PubMedGoogle Scholar
• Yuan H, Yu C, Li X, et al. Serum uric acid levels and risk of metabolic syndrome: a dose-response meta-analysis of prospective studies. J Clin Endocrinol Metab. 2015;100(11):4198–4207. doi:10.1210/jc.2015-2527.
   PubMed Web of Science ®Google Scholar
• Sirota JC, McFann K, Targher G, et al. Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: liver ultrasound data from the National Health and Nutrition Examination Survey. Metabolism. 2013;62(3):392–399. doi:10.1016/j.metabol.2012.08.013.
   PubMed Web of Science ®Google Scholar
• Demiray A, Afsar B, Covic A, et al. The role of uric acid in the acute myocardial infarction: a narrative review. Angiology. 2022;73(1):9–17. doi:10.1177/00033197211012546.
   PubMed Web of Science ®Google Scholar
• Kuwabara M, Hisatome I, Niwa K, et al. The optimal range of serum uric acid for cardiometabolic diseases: a 5-Year Japanese cohort study. J Clin Med. 2020;9(4):942. doi:10.3390/jcm9040942.
   PubMed Web of Science ®Google Scholar
• Stefan N, Schulze MB. Metabolic health and cardiometabolic risk clusters: implications for prediction, prevention, and treatment. Lancet Diabetes Endocrinol. 2023;11(6):426–440. doi:10.1016/S2213-8587(23)00086-4.
   PubMed Web of Science ®Google Scholar